FindTrial
Sign In

Effects of Vitamin A in patients of Acne Vulgaris

Risk-assessment of isotretinoin in acne vulgaris patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013060
Enrollment
50
Registered
2018-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Severe inflammatory Acne Vulgaris

Interventions

Intervention1: Isotretinoin: Oral capsule (0.5 â?? 2mg /kg) for 30 days

Sponsors

B J Medical College and Civil Hospital
Lead Sponsor
Dr Chandresh Dumatar
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients prescribed isotretinoin for treatment of severe acne vulgaris Patients willing to participate in the study and give written informed consent

Exclusion criteria

Exclusion criteria: Patients with mild or moderate acne Pregnant women Patients not willing to give written informed consent

Design outcomes

Primary

MeasureTime frame
AST, ALT, TG, LDL, HDLTimepoint: 3 months—

Secondary

MeasureTime frame
Detection of adverse drug reactionsTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Shaunak Sharma

B J Medical College Ahmedabad

drdumatar@gmail.com9426745911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026